Most topical studies track outcomes over 8-12 week windows, which is where the 6-8 week benchmark for visible changes comes from
The scalps barrier function prevents much of the applied peptide from reaching follicles
As a powerful antioxidant, glutathione may help reduce oxidative stress, a major factor in the development of cardiovascular disease
64% of infants receive acetaminophen within 48 hours after vaccination Acetaminophen used 2.6x more frequently than ibuprofen Why newborns are uniquely vulnerable: Glucuronidation severely underdeveloped (primary adult pathway barely functions) Sulfation predominates but easily saturated Limited glutathione reserves When sulfation is saturated, more acetaminophen is forced through the oxidative pathway to NAPQI The compounding effect: Before birth: Mother has compromised glutathione takes acetaminophen fetal brain exposed to NAPQI fetus cannot effectively detoxify After birth: Baby loses maternal protection immature detoxification receives acetaminophen at 2, 4, 6, 12 months with vaccinations cumulative burden may exceed threshold The math: 200,000+ pregnancies per year involve acetaminophen use in women with compromised glutathione Of those, 64% of infants receive acetaminophen after first vaccination That's approximately 128,000 infants per year with vulnerable prenatal exposure AND postnatal acetaminophen 100,000 children diagnosed with neurodevelopmental disorders annually This isn't about vaccines causing neurodevelopmental disorders
GHK-Cu is available in the following compounding formats: Topical direct skin application for dermatological benefits including collagen stimulation, wound healing, and pigmentation correction Hair foam scalp application to support hair growth and follicle health Hair dropper targeted scalp delivery for hair and follicle applications Troche sublingual dissolve for systemic absorption Frequently asked questions about GHK-Cu Q: Why does GHK-Cu need to be complexed with copper
